BIOFRONTERA 
By
Leverkusen, Germany, 20 January 2014 - The board of directors of Biofrontera AG (Biofrontera) has, with the approval of the supervisory board, resolved today to increase the registered capital of Biofrontera from currently EUR 17,753,168.00 by up to EUR 4,438,292.00 to up to EUR
22,191,460.00 by way of issuing up to 4.438.292 new shares with a par
value of EUR 1.00 ("New Shares") against cash payments.
The New Shares are entitled to a participation in profits from 1 January
2013. Shareholders will be offered the legal subscription right in such a way that Lang & Schwarz Broker GmbH, Düsseldorf, has been selected to subscribe and take over the New Shares at the par value of 1.00 EUR, with the obligation to offer them to the shareholders of the company at a ratio of
4:1 ("Subscription Offer") and a subscription price of EUR 3.50 per New
Share ("Subscription Price"). The subscription period will run from 21
January 2014 to 03 February 2014. If not all shares will be placed through the Subscription Offer, shareholders who have already exercised their subscription rights may subscribe additional shares at the same Subscription Price at Lang & Schwarz Broker GmbH by way of over- subscription. Further details of the Subscription Offer will be communicated in the Federal Gazette on 20 January 2014.
The company has further signed an agreement with one shareholder, Maruho Deutschland GmbH, Düsseldorf, according to which Maruho has committed to subscribe to New Shares at a total subscription value of EUR
10,000,000 (ten million Euro) within the subscription right and the over- subscription. Maruho Deutschland GmbH has also agreed that their New Shares shall be bound to a general lock up for a period of 24 months following the registration of the capital increase in the company's registry. Maruho Deutschland GmbH is a wholly owned subsidiary of Maruho Co., Ltd. (Maruho), a pharmaceutical company based in Osaka, Japan, which specializes in the development, production, and distribution of prescription
dermatological pharmaceuticals.
Page 1
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 22, Fax.: +49 (0214) 87 63 290
E-mail: press@biofrontera.com
Page 2
|
distributed by
|
